Humacyte Expands Board with Industry Veterans Scott Coward and Paul Kuznik

DURHAM, N.C., Sept. 28, 2026 /CourierPR/ -- Humacyte, a biotechnology company developing universally implantable, bioengineered human tissues, has expanded its board of directors with the addition of Scott Coward and Paul Kuznik, both industry veterans with extensive experience in commercialization, enterprise leadership, and global operations.

Scott Coward, a life science industry veteran, brings a wealth of experience from his tenure at Exact Sciences Corporation. Coward served as Executive Vice President, Chief Legal Officer, Chief Administrative Officer, and Secretary from January 2015 to December 2022. He led the integration of Genomic Health Corp. following its acquisition by Exact Sciences. Coward also served on the Exact Sciences board of directors from December 2022 to March 2026. Currently, he is an attorney at K&L Gates, where he has been since July 2026, and previously served as a partner from 2008 through 2014. Coward's experience includes public company board service and corporate governance, executive leadership within publicly traded life sciences companies, mergers and acquisitions, and post-acquisition integration, executive compensation, compliance and legal affairs, organizational leadership during periods of substantial growth and change, and partnering with executive management teams and boards through transformational corporate events.

Paul Kuznik, a medical technology executive with over three decades of experience in vascular healthcare, cardiovascular devices, and medical diagnostics, also joins the Humacyte Board. Kuznik served as the Chief Executive Officer and a member of the Board of Directors from 2015 to 2018 at Bolton Medical, a developer of endovascular technologies for complex aortic disease, which was acquired by Terumo Corporation. He helped lead the integration of Bolton Medical with Vascutek to create Terumo Aortic and subsequently served as President of Terumo Aortic United States from 2019 to 2020 and as President of Terumo Aortic North America from 2020 to 2023. Kuznik brings extensive experience in commercialization, enterprise leadership, organizational integration, strategic planning, manufacturing, clinical affairs, regulatory oversight, quality systems, physician engagement, and board governance.

Humacyte's Acellular Tissue Engineered Vessel (ATEV) received FDA approval in December 2024 for the treatment of vascular trauma. ATEVs are currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. The 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

Humacyte continues to advance its mission to deliver universally implantable bioengineered human tissues and advanced tissue constructs to improve patient care and transform the practice of medicine.